Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday

Sagimet Biosciences (NASDAQ:SGMT) is expected to be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect Sagimet Biosciences to post earnings of ($0.65) per share for the quarter.

Sagimet Biosciences (NASDAQ:SGMT) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.15. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Stock Performance

SGMT opened at $3.74 on Monday. The stock has a market capitalization of $114.72 million, a PE ratio of -2.62 and a beta of 2.57. Sagimet Biosciences has a one year low of $2.39 and a one year high of $7.38. The business’s 50 day moving average price is $4.28 and its 200 day moving average price is $4.46.

Analyst Ratings Changes

A number of analysts have issued reports on SGMT shares. Oppenheimer started coverage on Sagimet Biosciences in a research report on Friday, December 6th. They issued an “outperform” rating and a $30.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of Sagimet Biosciences in a research report on Tuesday, March 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.00.

Sagimet Biosciences Company Profile

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.